Angelo Minucci1, Maria De Bonis2, Elisa De Paolis2, Leonarda Gentile2, Concetta Santonocito2, Paola Concolino2, Flavio Mignone2, Ettore Capoluongo3. 1. Laboratory of Clinical Molecular and Personalized Diagnostics, Institute of Biochemistry and Clinical Biochemistry, Teaching and Research Hospital 'Agostino Gemelli' Foundation, Rome, Italy. angelo.minucci@virgilio.it. 2. Laboratory of Clinical Molecular and Personalized Diagnostics, Institute of Biochemistry and Clinical Biochemistry, Teaching and Research Hospital 'Agostino Gemelli' Foundation, Rome, Italy. 3. Laboratory of Clinical Molecular and Personalized Diagnostics, Institute of Biochemistry and Clinical Biochemistry, Teaching and Research Hospital 'Agostino Gemelli' Foundation, Rome, Italy. ettoredomenico.capoluongo@unicatt.it.
Abstract
INTRODUCTION: Detection of pathogenic variants in hereditary breast and ovarian cancer-related breast cancer type 1 and type 2 susceptibility proteins (BRCA1/2) genes is an effective strategy in cancer prevention and treatment. Some ethnic and geographical regions show different BRCA1/2 mutation spectrum and prevalence. In Italy, elucidation of founder effect in BRCA1/2 genes can have an impact on the management of hereditary cancer families on a healthcare system level, making genetic testing more affordable and cost effective in certain regions. METHODS: The purpose of this paper is to develop a rapid, low-cost, high-throughput single-tube technology for genotyping the Italian founder mutation c.4964_4982del19 (rs80359876) in the BRCA1 gene, starting from peripheral blood and/or buccal swab DNA. RESULTS: Heterozygote samples for c.4964_4982del19 variant were easily and unambiguously identified by the altered shape of the melting curves and were clearly distinguished by a change in melting temperature that differed by approximately 5 °C. The same results were obtained both with DNA from peripheral blood than buccal swab. CONCLUSIONS: We provide evidence about application of high-resolution melting analysis (HRMA) in unambiguously genotyping of the founder BRCA1 c.4964_4982del19 variant (rs80359876) in individuals from the Calabria region of Italy. In fact, HRMA was confirmed to be particularly suitable for the identification of BRCA1 c.4964_4982del19 variant, making this approach useful in clinical molecular diagnostics.
INTRODUCTION: Detection of pathogenic variants in hereditary breast and ovarian cancer-related breast cancer type 1 and type 2 susceptibility proteins (BRCA1/2) genes is an effective strategy in cancer prevention and treatment. Some ethnic and geographical regions show different BRCA1/2 mutation spectrum and prevalence. In Italy, elucidation of founder effect in BRCA1/2 genes can have an impact on the management of hereditary cancer families on a healthcare system level, making genetic testing more affordable and cost effective in certain regions. METHODS: The purpose of this paper is to develop a rapid, low-cost, high-throughput single-tube technology for genotyping the Italian founder mutation c.4964_4982del19 (rs80359876) in the BRCA1 gene, starting from peripheral blood and/or buccal swab DNA. RESULTS: Heterozygote samples for c.4964_4982del19 variant were easily and unambiguously identified by the altered shape of the melting curves and were clearly distinguished by a change in melting temperature that differed by approximately 5 °C. The same results were obtained both with DNA from peripheral blood than buccal swab. CONCLUSIONS: We provide evidence about application of high-resolution melting analysis (HRMA) in unambiguously genotyping of the founder BRCA1 c.4964_4982del19 variant (rs80359876) in individuals from the Calabria region of Italy. In fact, HRMA was confirmed to be particularly suitable for the identification of BRCA1 c.4964_4982del19 variant, making this approach useful in clinical molecular diagnostics.
Authors: F Baudi; B Quaresima; C Grandinetti; G Cuda; C Faniello; P Tassone; V Barbieri; R Bisegna; E Ricevuto; S Conforti; A Viel; P Marchetti; C Ficorella; P Radice; F Costanzo; S Venuta Journal: Hum Mutat Date: 2001-08 Impact factor: 4.878
Authors: Cameron N Gundry; Joshua G Vandersteen; Gudrun H Reed; Robert J Pryor; Jian Chen; Carl T Wittwer Journal: Clin Chem Date: 2003-03 Impact factor: 8.327
Authors: M A Caligo; C Ghimenti; G Cipollini; S Ricci; I Brunetti; V Marchetti; R Olsen; S Neuhausen; D Shattuck-Eidens; P F Conte; M H Skolnick; G Bevilacqua Journal: Oncogene Date: 1996-10-03 Impact factor: 9.867
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: G Palmieri; G Palomba; A Cossu; M Pisano; M F Dedola; M G Sarobba; A Farris; N Olmeo; A Contu; A Pasca; M P Satta; I Persico; A A Carboni; P Cossu-Rocca; M Contini; J Mangion; M R Stratton; F Tanda Journal: Ann Oncol Date: 2002-12 Impact factor: 32.976
Authors: Maria De Bonis; Angelo Minucci; Giovanni Luca Scaglione; Elisa De Paolis; Gianfranco Zannoni; Giovanni Scambia; Ettore Capoluongo Journal: Fam Cancer Date: 2019-01 Impact factor: 2.375
Authors: Maria De Bonis; Elisa De Paolis; Maria Elisabetta Onori; Giorgia Mazzuccato; Antonio Gatto; Pietro Ferrara; Pietro Manuel Ferraro; Andrea Urbani; Angelo Minucci Journal: Mol Biol Rep Date: 2021-04-17 Impact factor: 2.316
Authors: Giorgia Mazzuccato; Maria De Bonis; Vittoria Carboni; Claudia Marchetti; Andrea Urbani; Giovanni Scambia; Ettore Capoluongo; Anna Fagotti; Angelo Minucci Journal: Mol Biol Rep Date: 2020-05-28 Impact factor: 2.316
Authors: Alessandra Costella; Rossella De Leo; Donatella Guarino; Marco D'Indinosante; Paola Concolino; Giorgia Mazzuccato; Andrea Urbani; Giovanni Scambia; Ettore Capoluongo; Anna Fagotti; Angelo Minucci Journal: Hum Genome Var Date: 2018-06-08